Comment on FR Doc # 2026-10128
Anonymous AnonymousOpposeIndividual
Summary: A concerned citizen and prescription medication user opposes the proposed rule because it prioritizes manufacturing volume over product quality assurance for Schedule II CNS stimulants. The commenter argues that accelerated production has led to measurable degradation in medication quality and urges the DEA to mandate batch consistency data, pharmacological profiling, and patient-reported quality feedback in the final rule.
FORMAL PUBLIC COMMENT
Drug Enforcement Administration
Revision of Applications for Manufacturing and Procurement Qu
Docket No. DEA-1278
| RIN 1117-AB86
21 CFR Parts 1303 and 13
Federal Register Vol. 91, No. 97 |
Submitted: July 20, 2026
Submitted By: Concerned Citizen and Prescription Medication User
Regulatory Reference: Docket No. DEA-1278 / RIN 1117-AB86
Applicable CFR Sections: 21 CFR Parts 1303 and 1315
Comment Deadline: July 20, 2026 - Submitted via Regulations.gov
Position: OPPOSED - with affirmative recommendations for quality-based reform